Bentley gets OK for risperidone in Spain

8 May 2005

US specialty drug and generics maker Bentley Pharmaceuticals says that one of its Spanish subsidiaries, Laboratorios Davur, has received approval to market 1mg, 3mg and 6mg generic dosage versions of Janssen's Risperdal (risperidone) in Spain.

The drug belongs to a class of antipsychotic products used to treat schizophrenia. According to IMS, the market size of antipsychotic pharmaceutical products in Spain is approximately $415.0 million, of which, risperidone accounts for around $100.0 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight